Relationship between 5-fluorouracil disposition, toxicity and dihydropyrimidine dehydrogenase activity in cancer patients
Open Access
- 1 September 2001
- journal article
- clinical trial
- Published by Elsevier in Annals of Oncology
- Vol. 12 (9) , 1301-1306
- https://doi.org/10.1023/a:1012294617392
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- Correlation Between Uracil and Dihydrouracil Plasma Ratio, Fluorouracil (5-FU) Pharmacokinetic Parameters, and Tolerance in Patients With Advanced Colorectal Cancer: A Potential Interest for Predicting 5-FU Toxicity and Determining Optimal 5-FU DosageJournal of Clinical Oncology, 1999
- Profound variation in dihydropyrimidine dehydrogenase activity in human blood cells: major implications for the detection of partly deficient patientsBritish Journal of Cancer, 1999
- Dihydropyrimidine dehydrogenase deficiency and fluorouracil-related toxicityBritish Journal of Cancer, 1999
- Dihydropyrimidine dehydrogenase pharmacogenetics in patients with colorectal cancer.British Journal of Cancer, 1998
- Inter- and intraindividual variation in dihydropyrimidine dehydrogenase activity in peripheral blood mononuclear cellsCancer Chemotherapy and Pharmacology, 1997
- Individualizing Therapy with 5-Fluorouracil Related to Dihydropyrimidine Dehydrogenase: Theory and LimitsTherapeutic Drug Monitoring, 1996
- Depressed hepatic dihydropyrimidine dehydrogenase activity and fluorouracil-related toxicitiesThe American Journal of Medicine, 1995
- Population study of dihydropyrimidine dehydrogenase in cancer patients.Journal of Clinical Oncology, 1994
- cDNA cloning and chromosome mapping of human dihydropyrimidine dehydrogenase, an enzyme associated with 5-fluorouracil toxicity and congenital thymine uraciluria.Journal of Biological Chemistry, 1994
- Familial Pyrimidinemia and Pyrimidinuria Associated with Severe Fluorouracil ToxicityNew England Journal of Medicine, 1985